Asset Details
Do you wish to reserve the book?
Obesity enhances ovarian cancer chemotherapy efficacy through C1q-mediated tumor targeting and immune activation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Obesity enhances ovarian cancer chemotherapy efficacy through C1q-mediated tumor targeting and immune activation
Do you wish to request the book?
Obesity enhances ovarian cancer chemotherapy efficacy through C1q-mediated tumor targeting and immune activation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Obesity enhances ovarian cancer chemotherapy efficacy through C1q-mediated tumor targeting and immune activation
2025
Overview
Personalized protein corona significantly influences the biodistribution and therapeutic efficacy of nanomedicines, generating unique profiles that can impact treatment outcomes. Here, we demonstrate that pegylated liposomal doxorubicin (PLD) exhibits increased tumor accumulation and enhanced antitumor immunity in obese mice bearing ovarian tumor, inducing a greater capacity to inhibit tumor growth compared to normal mice. Mechanistically, the protein corona, particularly enriched with complement component 1q (C1q) in the plasma of obese mice, significantly enhances the internalization of PLD by ovarian cancer cells and elicits strong immunogenic cell death (ICD) effects. Concurrently, C1q adsorbed on PLD promotes the engulfment of apoptotic tumor cells by dendritic cells (DCs), activating T cell-mediated antitumor immune responses and amplifying the overall antitumor efficacy of PLD in obese mice. Our findings provide new insights into the role of the personalized protein corona in modulating the therapeutic response to chemotherapy and highlight the potential of targeting C1q for enhancing the efficacy of nanomedicines in cancer treatment.
Graphical Abstract
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Cancer
/ Chemistry and Materials Science
/ Complications and side effects
/ Dendritic Cells - drug effects
/ Dendritic Cells - immunology
/ Doxorubicin - analogs & derivatives
/ Doxorubicin - pharmacokinetics
/ Doxorubicin - therapeutic use
/ Female
/ Methods
/ Mice
/ Obesity
/ Ovarian Neoplasms - complications
/ Ovarian Neoplasms - drug therapy
/ Ovarian Neoplasms - immunology
/ Pegylated liposomal doxorubicin
/ Polyethylene Glycols - pharmacokinetics
/ Polyethylene Glycols - therapeutic use
